Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

PURPOSE: In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum...

Descripción completa

Detalles Bibliográficos
Autores principales: del Campo, Josep M., Matulonis, Ursula A., Malander, Susanne, Provencher, Diane, Mahner, Sven, Follana, Philippe, Waters, Justin, Berek, Jonathan S., Woie, Kathrine, Oza, Amit M., Canzler, Ulrich, Gil-Martin, Marta, Lesoin, Anne, Monk, Bradley J., Lund, Bente, Gilbert, Lucy, Wenham, Robert M., Benigno, Benedict, Arora, Sujata, Hazard, Sebastien J., Mirza, Mansoor R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839909/
https://www.ncbi.nlm.nih.gov/pubmed/31173551
http://dx.doi.org/10.1200/JCO.18.02238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839909/
https://www.ncbi.nlm.nih.gov/pubmed/31173551
http://dx.doi.org/10.1200/JCO.18.02238

Ejemplares similares